Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD
A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo-controlled Study to Assess the Effect of Lanthanum Carbonate on Intact FGF23 in Normo-phosphataemic Subjects With Stage 3 Chronic Kidney Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Paris
-
Saint Ouen, Paris, France, 93400
- Dr Pablo Urena Torres
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects meeting all of the criteria listed below may be included in the study:
- ≥18 years old.
- Male, or non-pregnant, non-lactating females who agree to comply with any applicable contraceptive requirements of the protocol.
- Been in the care of a physician for CKD for >2 months, and are not expected to begin dialysis for at least 6 months.
- Screening serum c-terminal FGF23 > 50.0RU/mL.
- Screening estimated glomerular filtration rate (eGFR) of 30-59mL/min/1.73m2 using the MDRD formula.
- Normal serum phosphate (0.808-1.55mmol/L).
- Endogenous 25-hydroxy Vitamin D levels >20ng/mL.
- Adequate protein diet (includes 2-3 portions of protein-rich food per day).
- An understanding, ability, and willingness to fully comply with study procedures and restrictions.
- Ability to provide written, signed, and dated (personally) informed consent to participate in the study.
Exclusion Criteria
- Vitamin D supplementation required.
- Compounds containing calcium, phosphate, aluminium or magnesium required.
- Acute renal failure.
- Rapidly progressing glomerulonephritis.
- Vegetarian diet.
- Known allergy to iodine.
- Clinically significant uncontrolled concurrent illness, which, in the opinion of the Investigator, would impair subjects' ability to give informed consent or take part in or complete this clinical study.
- Cirrhosis or other clinically significant liver disease (aspartate transaminase (AST) or alanine transaminase (ALT) >3 times the upper limit of normal or bilirubin >2 times the upper limit of normal).
- Past (treated within the last 5 years) or present GI disorders including uncontrolled peptic ulcer, Crohn's disease (or other conditions where the integrity of the GI tract may be compromised), malignancy, or GI bleed within the last 6 months.
- Life-threatening malignancy or current multiple myeloma.
- Known to be Human Immunodeficiency Virus (HIV) positive.
- History of poor compliance with diet or medication that in the Investigator's opinion may interfere with adherence to the protocol.
- History of alcohol or other substance abuse within 6 months prior to screening.
- Subjects must not have used another investigational medicinal product or taken part in a clinical trial within the last 30 days prior to enrolment.
- Subjects who have previously been enrolled into this study and subsequently withdrawn.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Matching placebo chewable tablets administered 3 times a day for 12 weeks
|
|
Experimental: Lanthanum carbonate
|
1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Natural Logarithm Transformed Serum Intact Fibroblast Growth Factor (FGF-23) Levels at Week 12 Last Observation Carried Forward (LOCF)
Time Frame: 12 Weeks
|
FGF-23 plays an important role in mineral metabolism in chronic kidney disease patients.
It is secreted by bone cells in response to hyperphosphatemia.
It acts to decrease renal phosphate reabsorption.
Administration of a phosphate-binder (i.e.
lanthanum carbonate) was expected to produce a reduction in FGF-23 levels.
|
12 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change From Baseline in Serum Intact Parathyroid Hormone (iPTH) Values at Week 12 (LOCF)
Time Frame: 12 Weeks
|
12 Weeks
|
|
Change From Baseline in 1,25-Dihydroxy Vitamin D Values at Week 12 (LOCF)
Time Frame: 12 weeks
|
12 weeks
|
|
Change From Baseline in Urinary Fractional Excretion of Phosphate Values at Week 12 (LOCF)
Time Frame: 12 weeks
|
12 weeks
|
|
Change From Baseline in Serum Phosphate Values at Week 12 (LOCF)
Time Frame: 12 weeks
|
12 weeks
|
|
Change From Baseline in Serum Total Calcium Values at Week 12 (LOCF)
Time Frame: 12 weeks
|
12 weeks
|
|
Change From Baseline in Calcium-Phosphate Product Values at Week 12 (LOCF)
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SPD405-703
- 2009-016531-35 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.